Compare AstraZeneca plc (AZN) vs HP Inc (HPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs HP Inc — how do they compare? AstraZeneca plc trades at $158.36 (market cap $248.14B), while HP Inc trades at $29.03 (market cap $26.59B). The key difference: AstraZeneca plc is far larger — about 9.3× HP Inc's market cap, and HP Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| AZN | HPQ | |
|---|---|---|
Market Cap | $248.14B | $26.59B |
Sector | Health | Technology |
52-Week High | $209.48 | $30.05 |
52-Week Low | $147.06 | $18.20 |
Enterprise Value | $275.41B | $33.75B |
Dividend Yield | 2.01% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
HPQ trades at $28.96, down 2.82% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue for 2025 reached $55.3 billion, with a net income margin of 4.45%, while valuation metrics like a P/E of 10.77 and P/S of 0.48 suggest potential undervaluation. Recent news highlights AI-driven cost savings and a profitable upgrade cycle, with Q2 FY2026 revenue up 9% year-over-year.
The outlook is mixed; HPQ benefits from solid cash flow and dividend yields near 4%, but faces risks from PC market declines and competitive pressures. Analyst consensus is cautious with a hold-heavy rating, and the stock trades above the consensus price target of $22, indicating limited upside. Investors should weigh steady profitability against industry headwinds and valuation constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
